Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings
NCT06522854 · University of Alabama at Birmingham · PHASE3 · withdrawn · last registry update 2025-09-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding not obtained” | – | Registry record, University of Alabama at Birmingham |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-28Results posted on the registry: National Jewish Health, Sildenafil 40mg oral capsule + Placebo Oral capsule (NCT04039087)
- 2026-08-12Phase 3 first posted: Ain Shams University, Tadalafil 5mg (NCT07761806)
- 2026-07-30Results posted on the registry: Vanderbilt University Medical Center, Tadalafil 20 MG + Placebo (NCT04684589)
- 2026-06-17Results posted on the registry: Respira Therapeutics, Inc., Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI) (NCT04266197)
- 2026-03-30Phase 3 first posted: Beni-Suef University, pentoxifylline 400 mg (NCT07499817)
- 2026-03-11Results posted on the registry: University of North Carolina, Chapel Hill, Sildenafil (NCT03142568)
- 2026-03-10Phase 3 first posted: Sindh Institute of Cardiovascular Diseases, Sildenafil 25 MG + Placebo (NCT07462260)
- 2026-02-23Also stopped (terminated): National Cancer Institute (NCI), nivolumab + tadalafil (NCT03785210)
- 2026-02-12Results posted on the registry: University of California, San Diego, Pembrolizumab + Tadalafil (NCT03993353)
- 2026-01-26Results posted on the registry: Christoph Hornik, Sildenafil + Placebo (NCT04447989)
- 2025-12-09Results posted on the registry: Mezzion Pharma Co. Ltd, Udenafil (NCT03013751)
- 2025-11-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tadalafil + Ambrisentan (NCT07245680)
- 2025-09-30Phase 3 first posted: Yunfeng Xia, Dipyridamole 50mg tid (NCT07199504)
- 2025-09-18Results posted on the registry: Mezzion Pharma Co. Ltd, Udenafil (NCT03430583)
- 2025-09-16Phase 3 first posted: Assiut University, Tadalafil 2.5 mg + Sildenafil 25 mg (NCT07177326)
- 2025-09-16Also stopped (withdrawn): University of Alabama at Birmingham, Sildenafil 50 mg Oral Tablet + Placebo Oral Tablet (NCT06377098)
- 2025-07-14Also stopped (withdrawn): Sadat City University, Sildenafil Citrate + Placebo oral tablet (NCT04344678)
- 2025-07-14Also stopped (withdrawn): Sadat City University, Tadalafil 5Mg Tab + Placebo (NCT05030623)
- 2025-07-04Results posted on the registry: Columbia University, Sildenafil (NCT04356716)
- 2025-06-11Results posted on the registry: Al-Azhar University, combination of Pentoxifylline 400 MG and Folic Acid + folic acid (NCT05284656)
- 2025-05-31Also stopped (withdrawn): Cedars-Sinai Medical Center, Pentoxifylline Oral Product + Placebo (NCT04391231)
- 2025-05-22Also stopped (terminated): Prokrea BCN, S.L., Vaginal product (NCT06986031)
- 2025-05-21Results posted on the registry: Mezzion Pharma Co. Ltd, Udenafil + Placebo (NCT02741115)
- 2025-05-06Results posted on the registry: Mezzion Pharma Co. Ltd, Udenafil (NCT02201342)
- 2025-02-21Results posted on the registry: Rutgers, The State University of New Jersey, Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (NCT04410328)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision